Menu

News and insights

Updates from Syncona and our portfolio companies

Filter by:

Type

Topic

Company

Reset
Autolus

20.04.2021

Autolus Therapeutics Receives Innovation Passport and entry into ILAP for AUTO4 for the treatment of T cell receptor constant region beta chain 1 (TRBC1) positive T cell lymphomas

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received innovative licensing and access pathway (ILAP) designation from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for AUTO4 being studied in a Phase 1 study in TRBC1 positive Peripheral T Cell Lymphoma (PTCL).
Resolution

12.04.2021

Resolution Therapeutics Appoints Lisa Bright to its Board of Directors

Experienced Non-Executive Director with strategic and operational leadership in global companies
Syncona

08.04.2021

Syncona Appoints Kenneth Galbraith as Executive in Residence

Syncona Ltd, a leading healthcare company focused on founding, building and funding a portfolio of global leaders in life science, announces the appointment of Kenneth Galbraith as Executive in Residence. Ken brings over 30 years’ experience in biotechnology and venture capital and will work alongside the Syncona Investment Management Limited team to support portfolio companies as they scale and develop.
Autolus

08.04.2021

Syncona Investor Webinar - Autolus: Developing Next Generation Programmed T Cell Therapies

Download (1.01Mb)
Autolus

01.04.2021

Autolus Therapeutics Receives PRIME designation for AUTO1 for the treatment of adult ALL

Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received PRIority MEdicines (PRIME) designation from the European Medicines Agency (EMA) for AUTO1, the company’s CAR T cell therapy being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory (r/r) adult B-Acute Lymphocytic Leukemia (ALL).
Freeline

31.03.2021

Freeline to Present at Upcoming Investor Conferences (1)

Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today announced that the Company will attend the following virtual investor conferences:
Achilles Therapeutics

31.03.2021

Achilles Therapeutics Announces Pricing of Initial Public Offering

Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced the pricing of its initial public offering in the United States of 9,750,000 American Depositary Shares (“ADSs”) representing 9,750,000 ordinary shares at an initial public offering price of $18.00 per ADS for total gross proceeds of $175.5 million.
Autolus

29.03.2021

Autolus Therapeutics Announces Updated Manufacturing Facility Strategy Leveraging its UK Operations

Autolus to expand on existing operations in the UK for commercial supply of AUTO1 resulting in a less capital-intensive commercial infrastructure strategy. Mutual agreement to terminate lease for the manufacturing and office facility at 9950 Medical Center Drive, Rockville, MD, resulting in a cash payment to Autolus
Anaveon

25.03.2021

Anaveon receives CTA approval to start a Phase I/II study to evaluate the safety, dosing and clinical activity of ANV419 in patients with solid tumors

ANV419 is a powerful and selective interleukin-2 (IL-2) agonist targeting cancer
Syncona

25.03.2021

Syncona: Gene and cell therapy overview

Download (1.13Mb)

Load More